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DNA samples from 339 Crohn’s disease (CD) and 407 randomly selected controls from the Auckland (New Zealand) IBD project,
were genotyped for ﬁve common single nucleotide polymorphisms in IL-23R (rs11805303, rs7517847, rs1343151, rs11209026,
and rs10889677) and two in IL-12B (rs1363670 and rs6887695). While the IL-12B variants did not show an overall association
and other IL23R variants led to minor changes in the risk of CD, rs1343151 and/or rs7517847 variants in the IL-23R gene strongly
reduced the risk of developing CD at both allelic and genotype levels. A signiﬁcantly decreased risk of ﬁrst diagnosis of childhood
CD was observed in individuals carrying the A allele of rs1343151, or between 17–40y in individuals carrying the G allele in
rs7517847 of IL-23R. A signiﬁcantly decreased risk of ileocolonic or structuring disease was observed in individuals carrying the A
allele in either rs11209026 or rs1343151, or the G allele in rs7517847 of IL-23R, and when such individuals did develop the disease,
theywereunlikelytorequireabowel resection.Certainhaplotypes verystronglymodiﬁedrisk.Therewas evidence forinteractions
of IL-23R variants with the NOD2 wild-type (d/d) genotype. Down-regulating the function of the IL-23R gene may decrease CD
risk in the normal population.
1.Introduction
The inﬂammatory bowel diseases, Crohn’s disease (CD)
and ulcerative colitis (UC), are common gastrointestinal
disorders in various countries, including New Zealand and
parts of Europe. In New Zealand, it appears that their
incidence is rising, and a geographically-based study in
the Canterbury region in 2005 identiﬁed close to 1 in
250 people with the disease [1]. CD is also increasing in
New Zealand paediatric patients [2]. Although mortality is
low, the symptoms can be debilitating, including abdominal
cramping and bloody diarrhoea. An increasing number
of studies are associating genes with susceptibility to the
disease. However, not all identiﬁed variants and genes show
comparable risks in diﬀerent countries [3].
Genome-wide association studies (GWAS) are rapidly
enhancing our understanding of key genetic polymorphisms
in CD, as in many other autoimmune disorders. Indeed, the
initial study on IL23R helped to provide proof of the power
of this technology to detect non-hypothesis based disease
associations [4]. Duerr and coworkers [5] utilised a well-
phenotyped population, by focussing on a single disease
type—ileal CD. As well as associations with two nucleotide
oligomerisation domain 2 (NOD2; alternatively known as
caspase activating recruitment domain or CARD15) variants
previously implicated in the disease, they also found a
strong disease association with chromosomal region 1p31,
which had not previously been implicated in CD. The
signal associated a single-nucleotide polymorphism (SNP)
of the gene encoding the interleukin-23 receptor (IL-23R),
not with increased disease risk but with decreased risk for
CD. The SNP, rs11209026, encodes an amino acid change
(Arg381Gln) in the protein product and has functional
consequences. Other analyses in two independent cohorts2 Gastroenterology Research and Practice
replicated this result, as well as uncovering disease relation-
ships with eight other related noncoding variants within IL-
23R [6, 7]. Interestingly, some of the closely located SNPs led
to protection while others were associated with an increased
riskofCD.Duerrandcoworkers[5]alsoinvestigatedSNPsin
the adjacent intergenic region containing the IL-12 receptor,
b-2 (IL-12RB2) gene, since this is mechanistically associated.
However,thisgenedidnotshowthesamestrongassociations
as those seen for IL-23R.
Ap r e v i o u ss t u d yb a s e di nC a n t e r b u r y ,N e wZ e a l a n d ,
associated IL-23R Arg381Gln with CD and possibly also UC
in that region of this country [8]. However, the authors
reported no signiﬁcant association between IL-23R genotype
and IBD phenotypes and also that the association was only
seen in those subjects who did not carry variant alleles in
NOD2. They did not consider other SNPs or other potential
interactions.
IL-23 is a cytokine that acts as a proinﬂammatory medi-
ator of autoimmune and chronic inﬂammatory diseases. In
association with IL-12, it is part of the T-helper 17 cell axis
[9]. The IL-12B gene, alternatively known as natural killer
cell stimulatory factor 2, cytotoxic lymphocyte maturation
factor 2, or p40, encodes the p40 subunit of IL-12B (ligand)
and IL-23R (receptor), both of which are dimeric proteins
[9]. The IL-12B gene contains two major sites, both of which
appear susceptible to variation and at which diﬀerent alleles
are associated with variable levels of gene expression. van de
Vosse and Ottenhoﬀ [10] reported that mutations in IL-12B
impair IL-12 and IL-23 responses and predispose subjects to
infections caused by mycobacteria and salmonella. Although
the original study by Duerr and coworkers [5] did not
associate variants in IL-12B with eﬀects in IL-23R, other
studies have done so [11, 12].
We have substantially expanded the available data on
the New Zealand situation, by considering a wider range of
variants in both IL-12B and IL-23R in our North Island CD
population, and by analysing associations with phenotype.
We have also done haplotype analyses and considered the
possibility of interactions of risk between SNPs in these
genes, and in NOD2.
2.MaterialsandMethods
2.1. Study Participants. The Auckland IBD Project is a
population-based study of genetic and environmental deter-
minants of CD aetiology. Patients were recruited between
May2005andApril2009throughlocaldoctorsandsurgeries
in Auckland, New Zealand, and also other North Island
centres. They also responded to media campaigns, for
example, local newspaper and television. Controls were also
recruited in a similar fashion and included nonaﬀected
spouses of the CD subjects. Participants consented to collec-
tionofperipheralbloodforDNAextractionandgenotyping,
and questionnaires were taken away for completion. Data
were scrutinised for accuracy and completion and subjects
recontacted for clariﬁcation where necessary.
Atotalof746subjects(339CDpatientsand407controls)
subjects consented to take part. The cases in this study
are a random subset of the Caucasian participants of the
Auckland IBD Project. CD was deﬁned using standard
diagnostic criteria [13]. Cases were phenotyped according
to the Montreal Classiﬁcation systems, allowing genotype-
phenotype analysis to be performed. CD diagnosis was
conﬁrmed in each patient by review of his or her case
notes. Patients were excluded from the cohort if there was
insuﬃcient information to conﬁrm a diagnosis of CD. All
participants self-reported European ancestry, and patients
who self-reported having any Maori or other non-Caucasian
ancestry were not included in the dataset. Clinical and
demographic characteristics of the Caucasian CD cohort for
this study are given in Table 1.
The study was conducted under ethical protocol
MEC/04/12/011, authorised through the New Zealand
Multi-Region Human Ethics Committee. All study subjects
gave informed consent. DNA was extracted from the blood
samples using Qiagen’s DNA extraction kit and following the
manufacturer’s instructions.
2.2. Genotyping. Genotyping for the polymorphisms in the
IL-12B gene (GenBank: NM 002187, g.158716689C > G,
rs1363670 and g.158755223G > C, rs6887695) and IL-23R
gene (GenBank: NM 144701, g.44034C > T, rs11805303;
g.50187T > G, rs7517847; g.87647G > A, rs1343151;
c.1142G > A, rs11209026 and c∗2370C > A, rs10889677)
used the MassARRAY and iPlex systems of the Sequenom
genotyping platform (Sequenom, San Diego, CA), which
uses the MALDI-TOF primer extension assay [14–16],
according to the manufacturers’ recommendations. How-
ever, this method failed for rs11209026, which was geno-
typed using the ABI TaqMan MGB diallelic discrimination
system. A custom-made, quality-controlled and functionally
testedgenotypingassay(Assay-by-Designonlineservice)was
obtained from Applied Biosystems (Melbourne, Australia).
All sample plates contained cases, controls, blanks,
and duplicate samples. Quality control measures including
independent double genotyping, blind to sample identity
and blind to the other caller and duplicates, were checked to
ensure that there were no discrepancies.
2.3. Statistical Analysis. The allelic trend test [17]a n d
Fisher’s exact genotypic test were used to compare
frequencies between case and control allele. An exact
test was used to test for departures from Hardy-Weinberg
equilibrium (HWE) in the case and the control samples [18].
Allelic odds ratios and conﬁdence intervals for the allelic
odds ratios were calculated under the assumption of HWE
in the cases and the control groups. We also used a Cochran-
ArmitageTrendtesttoconsiderallelicdiﬀerences.Amultiple
testing correction on phenotype analyses was conducted
using the false discovery rate (FDR). Linkage disequilibrium
(LD) for IL12B and IL23R for CEU population was evaluated
using Haploview 4.2, and the block was deﬁned by the Four
Gamete Rule (http://www.broadinstitute.org/haploview).
Haplotype analyses for IL12B (rs1363670 and rs6887695)
and IL23R (rs10889677, rs11805303, rs1343151, rs11209026,
and rs7517847) were carried out using haplo.stats packageGastroenterology Research and Practice 3
Table 1: Summary of Crohn’s disease and controls and Montreal classiﬁcation data.
Crohn’s disease n (%) Control group n (%)
Gender
Female 223 (68.4) 199 (37.3)
Male 103 (31.6) 335 (62.7)
Age at ﬁrst diagnosis
Below 17 30 (10.5)
Not applicable Between 17 and 40 204 (71.6)
Above 40 51 (17.9)
Crohn’s disease location
Colonic 86 (32.2)
Not applicable Ileal 97 (36.3)
Ileocolonic 84 (31.5)
Crohn’s disease behaviour
Inﬂammatory 152 (57.4)
Not applicable
Penetrating 32 (12.1)
Stricturing 81 (30.6)
Ileal/stricturing 47 (40.2)
Colonic/inﬂammatory 70 (59.8)
Any other families and relatives with IBD
Yes 88 (28.3) Not applicable
No 223 (71.7)
Bowel resection
Yes 99 (31.8) Not applicable
No 212 (68.2)
Smoker at diagnosis/smoker at interview
Yes 112 (46.7) 118 (29.4)
No 128 (53.3) 283 (70.6)
Extraintestinal manifestations
Yes 44 (14.2) Not applicable
No 267 (85.8)
in R [19] to test for association of these haplotypes with
CD. Haplotype frequencies were estimated, and association
analyses were performed with respect to CD in patients
and controls. A score for each haplotype (Hap-score) was
calculated. We also performed an exploratory analysis of
allele frequency diﬀerences between controls and patient
subgroups deﬁned using the clinical characteristics. These
analyses were carried out using R and SAS (V9.1 SAS
Institute., Cary, NC, USA).
The statistical interaction for CD-associated variants in
NOD2 with IL-12B and IL-23R was also investigated. The
three NOD2 SNPs (rs2066844, rs2066845, and rs2066847)
were classiﬁed as homozygous wild-type (d/d), heterozygous
carrier (d/D), or homozygous mutant carrier including
compound heterozygotes (D/D), as previously identiﬁed in
[20].
3. Results
3.1. Data Quality. Each of the 7 SNPs had a genotyping
call rate greater than 90% and was in HWE in the controls.
Although IL23R (rs1343151 and rs7517847) was out of
HWE in the CD cases, it demonstrated highly signiﬁcant
associations with IBD.
3.2. Characteristics of Case and Control Populations. Of 339
cases, 88 (28.3%) cases have other families and relatives
with IBD, 99 (31.8%) had bowel resections, 112 (46.7%)
smoked at diagnosis, and 44 (14.2%) showed extra intestinal
m a n i f e s t a t i o n so fC D( T a b l e1). The numbers of cases
successfully genotyped did not diﬀer from the number of
controls (data not shown).
3.3. Allelic and Genotype Diﬀerences. There were no overall
diﬀerences in allelic or genotype frequencies between cases
and controls for either of the variant alleles in IL-12B
(Table 2). However, there were signiﬁcant diﬀerences (P<
.05) between CD patients and controls in the allele frequency
for four IL23R SNPs (rs11209026, rs11805303, rs1343151,
and rs7517847) and in genotypic frequency for three IL23R
SNPs (rs10889677, rs1343151, and rs7517847).
For the rs10889677 SNP, the heterozygous A/C genotype
showed a signiﬁcantly increased risk of CD as compared
with the homozygous C/C genotype. For the rs112090264 Gastroenterology Research and Practice
Table 2: Genotype and allele counts for IL-12B and IL-23R variants in CD patients and in Caucasian controls.
Control n (%) Case n (%) OR (95% CI) P
IL-12B C/C 10 (2.9) 11 (3.6) 1.30 (0.54–3.12) .638
rs1363670 C/G 71 (20.8) 70 (23.3) 1.17 (0.80–1.70)
G/G 260 (76.3) 220 (73.1) 1.00
HWE 0.10 0.08
Cochran-Armitage Trend for G Z =− 0.95, Pr <Z 0.172
C 91 (13.3) 92 (15.3) 1.17 (0.86–1.60) .338
G 591 (86.7) 510 (84.7) 1.00
IL-12B C/C 39 (10.8) 29 (9.2) 0.79 (0.47–1.35) .625
rs6887695 C/G 177 (48.9) 148 (47.1) 0.89 (0.65–1.23)
G/G 146 (40.3) 137 (43.6) 1.00
HWE 0.21 0.25
C 255 (35.2) 206 (32.8) 0.90 (0.72–1.13) .358
G 469 (64.8) 422 (67.2) 1.00
IL-23R A/A 45 (12.5) 37 (11.8) 1.18 (0.72–1.93) .030
rs10889677 A/C 146 (40.6) 158 (50.5) 1.55 (1.12–2.15)
C/C 169 (46.9) 118 (37.7) 1.00
HWE 0.15 0.18
A 236 (32.8) 232 (37.1) 1.21 (0.96–1.52) .100
C 484 (67.2) 394 (62.9) 1.00
IL-23R A/A 5 (0.8) 0 (0) —
rs11209026 A/G 75 (11.9) 28 (8.0) 0.64 (0.41–1.01) .164
G/G 553 (87.4) 321 (92.0) 1.00
HWE 0.19 1.00
Cochran-Armitage Trend for G Z = 2.42, Pr >Z 0.008
A 85 (6.7) 28 (4.0) 0.58 (0.37–0.90) .015
G 1181 (93.3) 670 (96.0) 1.00
IL-23R C/C 173 (47.3) 123 (39.3) 1.00 .108
rs11805303 C/T 158 (43.2) 153 (48.9) 1.36 (0.99–1.88)
T/T 35 (9.6) 37 (11.8) 1.49 (0.89–2.49)
HWE 1.00 0.33
T 228 (31.1) 227 (36.3) 1.26 (1.01–1.58) .049
C 504 (68.9) 399 (63.7) 1.00
IL-23R A/A 56 (15.2) 16 (5.1) 0.29 (0.16–0.53) .0002
rs1343151 A/G 154 (41.7) 142 (45.4) 0.95 (0.69–1.30)
G/G 159 (43.1) 155 (49.5) 1.00
HWE 0.07 0.02
Cochran-Armitage Trend for G Z = 3.24, Pr >Z 0.0006
A 266 (36.0) 174 (27.8) 0.68 (0.54–0.86) .001
G 472 (64.0) 452 (72.2) 1.00
IL-23R G/G 72 (19.6) 29 (9.4) 0.42 (0.25–0.70) .001
rs7517847 G/T 183 (49.7) 172 (55.7) 0.98 (0.70–1.38)
T/T 113 (30.7) 108 (34.9) 1.00
HWE 0.92 0.001
G 327 (44.4) 230 (37.2) 0.74 (0.59–0.92) .007
T 409 (55.6) 388 (62.8) 1.00
SNP, a signiﬁcant decrease in the frequency of the A
allele was observed in CD patients. For the rs11805303
SNP, a signiﬁcant increase in the frequency of the T allele
was observed in CD. For the rs1343151 polymorphism, a
signiﬁcant decrease in the frequency of the A allele was
observedinCDpatients. Astronglydecreasedrisk ofCDwas
observed in A/A homozygous individuals as compared with
G/G homozygous individuals. Considering the rs7517847
polymorphism, a signiﬁcantly decreased frequency of the G
allele was observed in CD patients. A signiﬁcantly decreased
risk of CD was observed in G/G homozygote as compared
with T/T homozygous individuals.Gastroenterology Research and Practice 5
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Table 5: The statistical interaction between IL23R SNPs and NOD2 genotype.
NOD2
IL23R d/d (n = 557) d/D (n = 95) D/D (n = 19)
Control Case OR (95% CI) P Control Case OR (95% CI) P Control Case
rs10889677
A/A 40 27 0.81 (0.46–1.40) 8 8 0.35 (0.11–1.15) 0.147 0 1
A/C 130 109 1.00 .103 12 34 1.00 2 8
C/C 156 88 0.67 (0.47–0.97) 14 19 0.48 (0.19–1.24) 0 8
rs11209026
A/A 6 0 — 0 0 — 0 0
A/G 33 22 0.95 (0.54–1.68) .986 5 2 0.20 (0.04–1.08) 0.061 0 1
G/G 289 202 1.00 29 59 1.00 2 16
rs11805303
C/C 160 94 1.00 13 18 1.00 0.056 0 7
C/T 137 98 1.22 (0.85–1.75) .140 12 37 2.23 (0.85–5.85) 2 9
T/T 28 29 1.76 (0.99–3.14) 8 6 0.54 (0.15–1.94) 0 1
rs1343151
A/A 54 10 0.23 (0.11–0.47) 2 4 0.94 (0.16–5.69) 0.615 0 0
A/G 140 105 0.93 (0.65–1.33) .0003 16 22 0.65 (0.27–1.55) 0 9
G/G 134 108 1.00 16 34 1.00 2 8
rs7517847
G/G 64 24 0.45 (0.26–0.79) 4 3 0.60 (0.12–3.08) 0.156 0 0
G/T 172 121 0.84 (0.57–1.24) .018 14 36 2.06 (0.84–5.07) 2 6
T / T 9 17 6 1 . 0 0 1 62 0 1 . 0 0 0 1 0
Table 6: Frequency of NOD2 genotypes in the study sample.
Control N (%) CD N (%)
rs2066844
C/C 345 (94.8) 267 (86.7)
C/T 18 (5.0) 40 (13.0)
T/T 1 (0.3) 1 (0.3)
rs2066845
C/C 0 (0) 0 (0)
C/G 3 (0.8) 16 (5.2)
G/G 361 (99.2) 292 (94.8)
rs2066847
−/− 349 (95.9) 277 (89.9)
−/C 15 (4.1) 23 (7.5)
C/C 0 (0) 8 (2.6)
3.4. Phenotype Analyses. Phenotype analyses for IL-12B are
shown in Table 3(a), and for IL-23R in Table 3(b). A sig-
niﬁcantly decreased risk of CD was observed in individuals
carrying the A allele of rs1343151 in IL-23R in both females
and males or carrying the G allele in rs7517847 of IL-23R in
males.
A signiﬁcantly decreased risk of ﬁrst diagnosis of CD
under 17 years was observed in individuals carrying the A
allele of rs1343151 in IL-23R. A signiﬁcantly decreased risk
of age at ﬁrst diagnosis of CD between 17 and 40 years was
observed in individuals carrying the A allele of rs1343151 or
the G allele in rs7517847 of IL-23R.
Asigniﬁcantlydecreasedriskofilealdiseasewasobserved
in individuals carrying the C allele in rs6887695 of IL-12B.
Similarly, three of the variants of the IL-23R gene were
associated with having an increased risk of ileal disease. An
increased risk of ileal disease was evident for those carrying
the T allele in rs11805303 whilst a decreased risk of ileal
disease was associated with the A allele in rs1343151 and the
G allele in rs7517847 of IL-23R. A signiﬁcantly decreased risk
of ileocolonic disease was observed in individuals carrying
the A allele in rs11209026 and rs1343151 or the G allele in
rs7517847 of IL-23R.
A signiﬁcantly increased risk of stricturing disease was
observed in individuals carrying the C allele in rs1363670
of IL-12B. A signiﬁcantly decreased risk of inﬂammatory
disease was observed for those individuals carrying the A
allele in rs1343151 of IL-23R a signiﬁcantly decreased risk of
penetrating disease was also observed with this same SNP;
and a signiﬁcantly decreased risk of stricturing disease was
also observed with this same SNP. A signiﬁcantly increased
risk of stricturing disease was observed in individuals who
have the T allele in rs11805303; a signiﬁcantly decreased risk
of stricturing disease was observed in individuals who have
the A allele in rs11209026 and rs1343151 and individuals
who have the G allele in rs7517847 of IL-23R.
A signiﬁcantly increased risk of stricturing disease with
ileal involvement was observed in individuals who have
the C allele in rs1363670 of IL-12B and a signiﬁcantly
decreased risk of stricturing disease with ileal involvement
in individuals carrying the C allele in rs6887695 of IL-12B.
A signiﬁcantly decreased risk of stricturing disease with ilealGastroenterology Research and Practice 9
involvement was seen in individuals carrying the G allele in
rs7517847 of IL-23R.
Asigniﬁcantlydecreasedriskofhavinganyotherfamilies
and relatives with IBD was observed in individuals carrying
the A allele in rs1343151 and the G allele in rs7517847 of IL-
23R.
A signiﬁcantly decreased risk of CD requiring a bowel
resection was observed in individuals carrying the A allele in
rs11209026 and rs1343151 and the G allele in rs7517847 of
IL-23R. A signiﬁcant decrease in the risk of extra intestinal
manifestations (EIM) of CD was observed in individuals
carrying the A allele in rs10889677 and rs1343151.
The phenotypes which were signiﬁcantly associated with
both SNPs rs1343151 and rs7517847 of IL-23R remain
signiﬁcant after a multiple testing correction applied using
the FDR.
None of SNPs in this study was signiﬁcantly associated
with smoking at diagnosis.
3.5. Perianal Disease. A total of 42 (13.5%) CD patients had
perianal disease. For the rs10889677 SNP, the homozygous
A/A and the heterozygous A/C genotype showed a signiﬁ-
cantly increased risk of perianal disease as compared with
the homozygous C/C genotype. A signiﬁcant increase in the
frequencyoftheAallelers10889677wasobservedinperianal
patients.
For the rs1343151 SNP, the heterozygous A/G genotype
showed a signiﬁcantly decreased risk of perianal disease as
compared with the homozygous G/G genotype. A signiﬁcant
decrease in the frequency of the A allele rs1343151 was
observed in perianal patients.
3.6. Haplotype Analysis. Two SNPs of IL-12B and ﬁve SNPs
of IL-23R disequilibrium block were evaluated for haplotype
blocks using the four gamete rule in Haploview. Two
haplotype blocks were constructed for IL-23R (Figure 1),
and Tables 4(a) and 4(b) summarise these results. The
block 1 haplotype consisted of two SNPs (rs11805303 and
rs7517847). The hap-frequency of haplotype CG was 0.450
in control group, which is signiﬁcantly higher than that
in CD cases (0.358, P = .0005). The hap-frequency of
haplotype TT was 0.359 in CD cases, which is signiﬁcantly
higher than that in control group (0.305, P = .025). Block 2
haplotype consisted of three SNPs (rs10889677, rs11209026,
and rs1343151). The hap-frequency of haplotype CGA was
0.296 in the control group, which is signiﬁcantly higher than
that in CD cases (0.232, P = .007). The hap-frequency of
haplotype AGG was marginally signiﬁcantly higher in CD
cases (0.374) compared with that in control group (0.323,
P = .056)andCAAwasmarginallysigniﬁcantlyhigherinthe
control group (0.069) than in CD cases (0.044, P = .058).
No IL-12B haplotype was signiﬁcantly associated with CD
(P = .148).
3.7. Interaction between IL-23R and NOD2 with respect to
Crohn’s Disease. ThestatisticalinteractionforCD-associated
variants in NOD2 with IL-12B and IL-23R was investigated.
The frequencies and odds ratios of NOD2 risk genotypes
TT TT T T T T T GG G G GG G T T GG GG G CCC C C CA A AA A A
TT T T T GG G G G G GG CC C C C C C C C C AA A A AA A A A A AA
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Figure 1: IL23R LD plot.
stratiﬁed by IL-23R (rs10889677, rs11209026, rs11805303,
rs1343151, and 7517847) are shown in Table 5, while Table 6
shows frequencies of genotypes of the three NOD2 SNPs. A
statistical interaction was detected between rs1343151 and
NOD2, whereby carrying the genotype A/A signiﬁcantly
decreased the risk of CD on the background of NOD2
genotype d/d. For rs7517847, the genotype G/G showed
signiﬁcantly decreased risk of CD in those individuals with
the NOD2 genotype d/d. No signiﬁcant interactions were
found between rs10889677, rs11209026, rs11805303, or IL-
12BandNOD2genotype.Theoddsratiosonthebackground
of NOD2 genotype D/D were not calculated, due to small
numbers of D/D cases and controls.
4. Discussion
This study conﬁrms the very strong involvement of IL-23R
and, to a lesser extent, IL-12B, in Crohn’s disease in New
Zealand.ItisofinterestthatDuerrandcoworkers[5]utilised
aCDpopulationofonlyasinglephenotype—thosewithileal
involvement—in their original study which uncovered the
involvement of IL-23R in CD risk. Our own data conﬁrms
a relationship with ileal involvement for several of the10 Gastroenterology Research and Practice
SNPs studied. The association of this particular variant SNP,
rs11209026 (R381Q), in this gene with decreased risk of
CD has been conﬁrmed in paediatric populations [6, 7]
and also in the large UK database studied by the Wellcome
Trust Case Control Consortium [21]. Positive results of
varyingqualityandsigniﬁcancehavealsobeenreportedfrom
other populations, including Scotland, Continental Europe,
North America, New Zealand, Brazil, and Israel [8, 22–27].
However,noassociationswereseeninaJapanesecohort[28].
The majority of these studies have focussed on the R381Q
allele.Inourownstudies,dataforthisalleleprovidenowhere
near the statistical signiﬁcance of other allelic variants in
this gene. Our study suggests that rs11209026 may be less
important than other markers and also conﬁrms that even
closely related SNPs may have opposite eﬀects on CD risk.
Several of them are associated with paediatric disease.
Considering IL-12B, carrying the rs1363670 C variant
increases CD risk while carrying the rs6887695 C variant
decreases CD risk. In regard to the IL-23R gene, the
rs10889677 A variant and the rs11805303 T variant both
increase disease risk while both the rs1343151 variant A and
the rs7517847 G variant reduce disease risk. That is, some of
thesecloselylocatedSNPsledtoprotectionwhileotherswere
associated with an increased risk of CD. Similar results were
originally published by Duerr et al. [5], who suggested that
these apparently contradictory results might be explained by
alternative splicing of IL-23R.
For several other alleles in both IL12B and IL-23R,o u r
own data have conﬁrmed the observations of strong ileal
involvement [5]. In particular, a highly signiﬁcant increased
riskofilealdiseasewasobservedinindividualscarryingtheC
allele in rs6887695 of IL-12B. Similarly, one of the variants in
theIL-23Rgenedecreasedtheriskofilealdisease(theTallele
in rs11805303) while two increased the risk of ileal disease
(the A allele of rs1343151 or the G allele of rs7517847). Even
stronger statistical signiﬁcance was observed for ileo-colonic
disease in individuals carrying the A allele of rs1343151
or the G allele in rs7517847 of IL-23R. Although the risk
of inﬂammatory disease with colonic involvement was not
signiﬁcantly associated with any of the variant SNPs in
this study, there were strong associations with stricturing
disease for most of the studied SNPs. It is also important
that carrying either of two of the IL-23R SNPs signiﬁcantly
increased the probability that a bowel resection will be
required.
Early studies on CD had considered IL-12B as a can-
didate gene for CD susceptibility, partly because IL-12 is
upregulated in active disease [29–31]. Interleukin-12 is a
dimeric protein, consisting of two subunits, p35 and p40, the
latter of which is encoded by the IL-12B gene. In an animal
model of CD, it proved possible to suppress established
chronic intestinal inﬂammation by the use of antibodies
to the p40 subunit [32]. It should be noted, however, that
antibodies to p40 also suppress the activity of IL-23, since
these two cytokines have the p40 subunit in common. The
most likely interpretation of the accumulating set of data is
that IL-23 plays a more important role than IL-12 in chronic
inﬂammation. IL-23 activates a subset of T cells (TH17 T-
cells) leading to the production of the cytokine IL-17,w h i c h
modulates chronic inﬂammatory diseases. Kobayashi et al.
[33] provide evidence that IL-23 diﬀerentially regulates the
Th1/Th17 balance in inﬂammatory bowel diseases.
The present study adds to an increasing number of
reports of IL-23R importance in susceptibility to autoim-
munediseases. Severalreportshavedemonstratedsigniﬁcant
associations between carriage of variants in the IL-23R with
psoriasis vulgaris, psoriatic arthritis, autoimmune thyroid
disease, and Graves’ ophthalmopathy, but not with arthritis
per se, or myocardial infarct [34–37]. It is of some interest
that we have found associations with extra intestinal mani-
festations of disease in the present study.
The functionality of several of the SNPs studied here is
currently unknown. Considering possible eﬀects of the SNPs
studied in IL-23R, rs10889677 is located in the 3  untrans-
lated region and the variant may lead to overexpression of
the receptor. Similarly, each of the other three SNPs is in an
intragenic region and may also aﬀect receptor expression.
Receptor overexpression would enhance the release of IL-
17, because it would enhance the diﬀerentiation of Th1
helper T cells towards a Th17 subpopulation. Flow-on eﬀects
would lead to the release of other cytokines such as TNF-
alpha, thereby enhancing chronic inﬂammation. The SNPs
in IL-12B may be in linkage disequilibrium with a functional
variant. It will be important that future studies begin with
more speciﬁc information on functionality of the SNPs,
preferably based on eﬀects from human studies rather than
tissue culture models.
The present study supports other observations that
reducing the expression of IL-23R may provide an important
therapeutic target, not only for CD but also for other
diseases. It was shown that blocking the activity of either
IL-23 itself or its downstream factors IL-17 and IL-6 signiﬁ-
cantly impeded the development of disease in animal models
of IBD and multiple sclerosis [38, 39]. More speciﬁcally,
Becker and coworkers [40] showed that blocking the p40
subunit of either IL-12 or IL-23, but not blocking the
p19 unit, was eﬀective in reducing disease symptoms in
chemically induced colitis models. The same results were not
seen after blocking the IL-12/interferon-gamma pathways.
Conversely, enhancing TH17-cell-driven inﬂammation by
treatment with prostaglandin analogues shifts the balance
between IL-12 and IL-27 as compared with IL-23 [41]a n d
has adverse eﬀects on the disease. Thus, there is good
reason to suggest that therapies targeting the IL-23/IL-17
pathway may provide a useful approach to the treatment of
chronic inﬂammatory diseases. Elsewhere, we describe the
development of a high throughput screen to test for agents
with this ability [42]. It is noteworthy that several nutrients
a r ea b l et oa ﬀect this target, and we have previously shown
thatnutritionplaysaverysigniﬁcantroleinthedevelopment
and symptomatology of the disease [43]. Thus, while much
of the literature to date has focussed on the possibility of
monoclonal antibodies or other pharmaceutical approaches,
the possibility of nutritional intervention against this tar-
get should not be dismissed. Both pharmacogenomic and
nutrigenomicapproachesmaybeimportant in thecontrolof
disease in individuals carrying risk variants in IL-12B and/or
IL-23R [3, 42, 43].Gastroenterology Research and Practice 11
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